Stock SCOL SCANDION ONCOLOGY A/S
Add to a list
To use this feature you must be a member
Log inSign up

Scandion Oncology A/S Stock

Equities

SCOL

DK0061031895

Biotechnology & Medical Research

Delayed Nasdaq Stockholm
Other stock markets
 11:29:30 2024-04-23 am EDT 		5-day change 1st Jan Change
1.445 SEK -9.12% Intraday chart for Scandion Oncology A/S -42.20% -63.83%
Mar. 21 Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival CI
Mar. 07 Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial CI

Financials

Sales 2022 - Sales 2023 - Capitalization 109M 1.18B
Net income 2022 -76M -821M Net income 2023 -39M -421M EV / Sales 2022 -
Net cash position 2022 76.01M 821M Net cash position 2023 26.02M 281M EV / Sales 2023 -
P/E ratio 2022
-0.99 x
P/E ratio 2023
-2.78 x
Employees 4
Yield 2022 *
-
Yield 2023
-
Free-Float 94.68%
More Fundamentals * Assessed data

Chart Scandion Oncology A/S

Dynamic Chart

Latest news about Scandion Oncology A/S

Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival CI
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial CI
Transcript : Scandion Oncology A/S, Q4 2023 Earnings Call, Feb 28, 2024
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Scandion Oncology A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Scandion Oncology A/S - Special Call
Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial CI
Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101 CI
Scandion Oncology Announces Presenting Topline Data in the Ongoing Corist Part 3 Study CI
Scandion Oncology Completes Pre-Clinical Studies and Identifies Potentially Effective Treatment of Gastric Cancer CI
Scandion Oncology Obtains Patent for Combination Cancer Treatment Drug MT
Transcript : Scandion Oncology A/S, Nine Months 2023 Earnings Call, Nov 22, 2023
Scandion Oncology A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Scandion Oncology Announces Positive Data from Part 2 of its International Multi-Center CORIST Open Label Phase IIa Trial CI
Scandion Oncology Successfully Completes Phase Ib Pantax Trial Is and Establishes the Maximal Tolerated Dose with Positive Safety Profile and Pharmacokinetic Data CI
More news

Latest transcript on Scandion Oncology A/S

Logo Scandion Oncology A/S
Scandion Oncology A/S, Q4 2023 Earnings Call, Feb 28, 2024
More transcripts

Press releases Scandion Oncology A/S

Scandion Oncology – Notice convening the Annual General Meeting AQ
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival AQ
Scandion Oncology - Annual Report 2023 AQ
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial AQ
Scandion Oncology Q4 2023 - Striving towards randomised controlled data AQ
More press releases

Quotes and Performance

1 day-9.12%
1 week-42.20%
Current month-42.43%
1 month-29.51%
3 months-67.78%
6 months+25.43%
Current year-63.83%
More quotes

Highs and lows

1 week
0.90
Extreme 0.9
2.58
1 month
0.90
Extreme 0.9
3.48
Current year
0.90
Extreme 0.9
5.64
1 year
0.90
Extreme 0.9
5.64
3 years
0.90
Extreme 0.9
23.00
5 years
0.90
Extreme 0.9
75.00
10 years
0.90
Extreme 0.9
75.00
More quotes

Managers and Directors - Scandion Oncology A/S

Managers TitleAgeSince
Jan Stenvang FOU
 Founder - 16-12-31
François Martelet CEO
 Chief Executive Officer 64 23-01-01
Johnny Stilou DFI
 Director of Finance/CFO 57 21-07-31
Members of the board TitleAgeSince
Alejandra Maria Mørk BRD
 Director/Board Member 62 22-03-31
Jørgen Vilhelm Bardenfleth BRD
 Director/Board Member 69 18-05-06
Martin Møller CHM
 Chairman 49 21-04-30
More insiders

Quotes

Date Price Change Volume
24-04-23 1.445 -9.12% 93,277
24-04-22 1.59 -0.63% 73,490
24-04-19 1.6 -35.48% 1,530,600
24-04-18 2.48 +2.48% 8,478
24-04-17 2.42 -3.20% 16,933

Delayed Quote Nasdaq Stockholm, April 23, 2024 at 11:29 am EDT

More quotes

Company Profile

Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.
Sector
Biotechnology & Medical Research
Calendar
2024-04-23 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SCANDION ONCOLOGY A/S Stock Scandion Oncology A/S
-63.83% 5.43M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.49% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.31% 97.5B
ARGENX SE Stock argenx SE
+2.01% 22.19B
BIONTECH SE Stock BioNTech SE
-16.16% 21.33B
GENMAB A/S Stock Genmab A/S
-6.82% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.41% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-22.87% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.32% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.46% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SCOL Stock